345 related articles for article (PubMed ID: 22820319)
1. Ethical considerations and rationale of the MAKI trial: a multicenter double-blind randomized placebo-controlled trial into the preventive effect of palivizumab on recurrent wheezing associated with respiratory syncytial virus infection in children with a gestational age of 33-35 weeks.
Blanken M; Rovers M; Sanders E; Bont L
Contemp Clin Trials; 2012 Nov; 33(6):1287-92. PubMed ID: 22820319
[TBL] [Abstract][Full Text] [Related]
2. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants.
Blanken MO; Rovers MM; Molenaar JM; Winkler-Seinstra PL; Meijer A; Kimpen JL; Bont L;
N Engl J Med; 2013 May; 368(19):1791-9. PubMed ID: 23656644
[TBL] [Abstract][Full Text] [Related]
3. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing.
Simoes EA; Groothuis JR; Carbonell-Estrany X; Rieger CH; Mitchell I; Fredrick LM; Kimpen JL;
J Pediatr; 2007 Jul; 151(1):34-42, 42.e1. PubMed ID: 17586188
[TBL] [Abstract][Full Text] [Related]
4. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
[TBL] [Abstract][Full Text] [Related]
5. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
Romero JR
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
[TBL] [Abstract][Full Text] [Related]
6. Effect of palivizumab prophylaxis on subsequent recurrent wheezing in preterm infants.
Yoshihara S; Kusuda S; Mochizuki H; Okada K; Nishima S; Simões EA;
Pediatrics; 2013 Nov; 132(5):811-8. PubMed ID: 24127479
[TBL] [Abstract][Full Text] [Related]
7. Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial.
Man WH; Scheltema NM; Clerc M; van Houten MA; Nibbelke EE; Achten NB; Arp K; Sanders EAM; Bont LJ; Bogaert D
Lancet Respir Med; 2020 Oct; 8(10):1022-1031. PubMed ID: 32203712
[TBL] [Abstract][Full Text] [Related]
8. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?
Hashmi NA; Cosgrove JF; MacMahon P
Ir Med J; 2000 Dec; 93(9):284. PubMed ID: 11209917
[TBL] [Abstract][Full Text] [Related]
9. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
;
Pediatrics; 2014 Aug; 134(2):e620-38. PubMed ID: 25070304
[TBL] [Abstract][Full Text] [Related]
10. Respiratory syncytial virus prevention and asthma in healthy preterm infants: a randomised controlled trial.
Scheltema NM; Nibbelke EE; Pouw J; Blanken MO; Rovers MM; Naaktgeboren CA; Mazur NI; Wildenbeest JG; van der Ent CK; Bont LJ
Lancet Respir Med; 2018 Apr; 6(4):257-264. PubMed ID: 29500030
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial.
O'Brien KL; Chandran A; Weatherholtz R; Jafri HS; Griffin MP; Bellamy T; Millar EV; Jensen KM; Harris BS; Reid R; Moulton LH; Losonsky GA; Karron RA; Santosham M;
Lancet Infect Dis; 2015 Dec; 15(12):1398-408. PubMed ID: 26511956
[TBL] [Abstract][Full Text] [Related]
12. Palivizumab Prophylaxis in Preterm Infants and Subsequent Recurrent Wheezing. Six-Year Follow-up Study.
Mochizuki H; Kusuda S; Okada K; Yoshihara S; Furuya H; Simões EAF;
Am J Respir Crit Care Med; 2017 Jul; 196(1):29-38. PubMed ID: 28152315
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria.
Resch B; Sommer C; Nuijten MJ; Seidinger S; Walter E; Schoellbauer V; Mueller WD
Pediatr Infect Dis J; 2012 Jan; 31(1):e1-8. PubMed ID: 21960187
[TBL] [Abstract][Full Text] [Related]
14. Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants.
Pediatrics; 1998 Sep; 102(3):531-7. PubMed ID: 9724660
[TBL] [Abstract][Full Text] [Related]
15. [Palivizumab--a monoclonal antibody for passive immunoprophylaxis of respiratory syncytial virus infections].
Scholz H
Z Geburtshilfe Neonatol; 2000; 204(3):120-2. PubMed ID: 10909169
[TBL] [Abstract][Full Text] [Related]
16. Recurrent wheezing in the third year of life among children born at 32 weeks' gestation or later: relationship to laboratory-confirmed, medically attended infection with respiratory syncytial virus during the first year of life.
Escobar GJ; Ragins A; Li SX; Prager L; Masaquel AS; Kipnis P
Arch Pediatr Adolesc Med; 2010 Oct; 164(10):915-22. PubMed ID: 20921348
[TBL] [Abstract][Full Text] [Related]
17. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis.
Giebels K; Marcotte JE; Podoba J; Rousseau C; Denis MH; Fauvel V; Laberge S
Pediatr Pulmonol; 2008 Feb; 43(2):169-74. PubMed ID: 18085710
[TBL] [Abstract][Full Text] [Related]
18. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
Pedraz C; Carbonell-Estrany X; Figueras-Aloy J; Quero J;
Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
[TBL] [Abstract][Full Text] [Related]
19. Respiratory disorders and hospitalization rates during the second RSV season in preterm infants who received palivizumab prophylaxis during their first RSV season.
Fanos V; Scarcella A; Puddu M; Gallini F; Tuminelli F; Bragetti P; Gallina MR; Quartulli L; Benincori N; Citro G; Via LD; Barera G; DI Luzio Paparatti U; Merolla R; Romano GV; Guida G; Silvestri M; Rossi GA
J Chemother; 2009 Jun; 21(3):302-10. PubMed ID: 19567351
[TBL] [Abstract][Full Text] [Related]
20. Long-term consequences of respiratory syncytial virus (RSV) bronchiolitis.
Bont L; Aalderen WM; Kimpen JL
Paediatr Respir Rev; 2000 Sep; 1(3):221-7. PubMed ID: 12531083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
